Studies

Adjuvant Treatment with Empagliflozin or Semaglutide Increases Endothelial Progenitor Cells in Subjects with Well-Controlled Type 1 Diabetes Mellitus.

Current issues in molecular biology|2025|Preložnik Navodnik M et al.|2 citations

Circulating endothelial cells (CECs) and endothelial progenitor cells (EPCs) are promising markers of vascular damage and endothelial regeneration potential. We focused on the detection of CECs and EPCs using flow cytometry with regard to analytical…

Semaglutide

PMID: 39852169

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence.

Journal of cardiovascular development and disease|2025|Krishnan S et al.|3 citations

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists (GIP/GLP-1 RAs) are emerging as effective treatments for obesity and cardiometabolic disease. This study evaluated physicia…

Is Weight Loss the Main Driver for A1C Improvement by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists? A 2.5-Year Analysis in Real-World Clinical Practice.

Journal of diabetes|2025|Al-Badri M, Dhaver S, Hamdy O

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are established treatment options for type 2 diabetes (T2D). In addition to their glycemic benefit, GLP-1 RAs also induce weight loss by suppressing appetite via hypothalamic pathways.…

Semaglutide

PMID: 39853913

Semaglutide administration protects cardiomyocytes in db/db mice via energetic improvement and mitochondrial quality control.

Acta pharmacologica Sinica|2025|Tian M et al.|2 citations

Diabetic cardiomyopathy causes end-stage heart failure, resulting in high morbidity and mortality in type 2 diabetes mellitus (T2DM) patients. Long-term treatment targeting metabolism is an emerging field in the treatment of diabetic cardiomyopathy.…

Animal StudySemaglutide

PMID: 39856432

Integrated Management of Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs.

Biomedicines|2025|Theodorakis N, Nikolaou M|23 citations

Cardiovascular-Kidney-Metabolic syndrome, introduced by the American Heart Association in 2023, represents a complex and interconnected spectrum of diseases driven by shared pathophysiological mechanisms. However, this framework notably excludes the…

ReviewSemaglutide Tirzepatide

PMID: 39857719

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial.

Biomolecules|2025|Petković-Dabić J et al.|22 citations

Psoriasis is a chronic inflammatory skin disease with relapsing nature. Estimates are that approximately 2-3% of the world's population suffers from this disease. More severe forms of psoriasis are conditions of high inflammation, which is confirmed…

Randomized Controlled TrialSemaglutide

PMID: 39858442

The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study.

Pharmaceuticals (Basel, Switzerland)|2025|Kitsunai H et al.|1 citation

BACKGROUND/OBJECTIVES: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important common comorbidity in subjects with type 2 diabetes, and liver fibrosis is a factor directly related to its prognosis. Glucagon-like peptide-1 rec…

Semaglutide

PMID: 39861190

Allodynia (skin tenderness) associated with semaglutide: A case series.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists|2025|Stark J, Klass M, Owen L|3 citations

PURPOSE: The glucagon-like peptide-1 receptor agonist (GLP-1RA) class of medications are widely prescribed for management of diabetes mellitus as well as obesity or weight management. Although there have been rare reports of skin hypersensitivity ass…

Case ReportSemaglutide

PMID: 39862389

Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study.

Journal of the American Academy of Dermatology|2025|Burke O et al.|11 citations

Semaglutide Tirzepatide

PMID: 39863171

Semaglutide and laparoscopic sleeve gastrectomy in an adolescent with congenital adrenal hyperplasia due to 21-hydroxylase: a case report.

Journal of medical case reports|2025|Vidmar A et al.

BACKGROUND: Classic congenital adrenal hyperplasia, primarily due to 21-hydroxylase deficiency, leads to impaired cortisol and aldosterone production and excess adrenal androgens. Lifelong glucocorticoid therapy is required, often necessitating supra…

Case ReportSemaglutide

PMID: 39863876

Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map.

International journal of obesity (2005)|2025|Lu T et al.|3 citations

BACKGROUND: Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance. However, f…

ReviewSemaglutide Tirzepatide

PMID: 39865161

Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use Disorder.

Current neuropharmacology|2025|Sharafshah A et al.|7 citations

INTRODUCTION: Glucagon-Like Peptide-1 Receptor (GLP1R) agonists have become widespread anti-obesity/diabetes pharmaceuticals in the United States. AIM: This article aimed to provide our current knowledge on the plausible mechanisms linked to the role…

Semaglutide

PMID: 39865816

The use of an automatic remote weight management system to track treatment response, identified drugs supply shortage and its consequences: A pilot study.

Digital health|2025|Roth I, Cohen O|1 citation

OBJECTIVE: The objective of this pilot study is to evaluate the feasibility of using an automatic weight management system to follow patients' response to weight reduction medications and to identify early deviations from weight trajectories. METHODS…

Semaglutide

PMID: 39866891

Semaglutide and nonarteritic anterior ischaemic optic neuropathy.

Drug and therapeutics bulletin|2025|Unknown authors

Semaglutide

PMID: 39870391

Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data.

Expert review of endocrinology & metabolism|2025|Singh H, Natt N, Nim D|5 citations

BACKGROUND: Glucagon-like peptide-1 (GLP-1) agonists are commonly prescribed for type 2 diabetes mellitus (T2DM). Concerns have emerged regarding their potential link to diabetic retinopathy (DR). METHODS: To evaluate the association between GLP-1 ag…

Semaglutide Tirzepatide

PMID: 39873334

The GLP-1 agonist semaglutide ameliorates cognitive regression in P301S tauopathy mice model via autophagy/ACE2/SIRT1/FOXO1-Mediated Microglia Polarization.

European journal of pharmacology|2025|Elbadawy N et al.|9 citations

Tau hyper-phosphorylation has been recognized as an essential contributor to neurodegeneration in Alzheimer's disease (AD) and related tauopathies. In the last decade, tau hyper-phosphorylation has gained considerable concern in AD therapeutic develo…

Animal StudySemaglutide

PMID: 39875022

Sleeve Gastrectomy Versus Semaglutide for Weight Loss in a Severely Obese Minority Cohort: A Propensity-Matched Study.

Obesity surgery|2025|Masrur M et al.|6 citations

BACKGROUND: The rising obesity rates in the USA have led to a surge in various weight loss treatments. Glucagon-like peptide-1 (GLP-1) analogues have shown promise in reducing weight but primarily studied in Caucasian populations. Sleeve gastrectomy…

Semaglutide

PMID: 39875789

Changes in food preferences after oral semaglutide administration in Japanese patients with type 2 diabetes: KAMOGAWA-DM cohort.

Diabetes & vascular disease research|2025|Hironaka J et al.|3 citations

BACKGROUND: This study aimed to investigate the effects of oral semaglutide on the changes in food preference of Japanese patients with type 2 diabetes. METHODS: This retrospective multicenter study included 75 patients with type 2 diabetes who recei…

Semaglutide

PMID: 39878627

Longitudinal Analysis of Obesity Drug Use and Public Awareness.

JAMA network open|2025|Berning P et al.|36 citations

IMPORTANCE: Obesity, a chronic disease with escalating global prevalence, poses considerable health risks. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), including liraglutide, semaglutide, and tirzepatide, have demonstrated efficacy for weigh…

Semaglutide Tirzepatide

PMID: 39878977

Adjuvant Treatment with Empagliflozin or Semaglutide Increases Endothelial Progenitor Cells in Subjects with Well-Controlled Type 1 Diabetes Mellitus.

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence.

Is Weight Loss the Main Driver for A1C Improvement by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists? A 2.5-Year Analysis in Real-World Clinical Practice.

Patients Are Flocking to Compounded Weight-Loss Drugs, but Are They Safe?

Semaglutide administration protects cardiomyocytes in db/db mice via energetic improvement and mitochondrial quality control.

Integrated Management of Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs.

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial.

The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study.

Allodynia (skin tenderness) associated with semaglutide: A case series.

Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study.

Semaglutide and laparoscopic sleeve gastrectomy in an adolescent with congenital adrenal hyperplasia due to 21-hydroxylase: a case report.

Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map.

Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use Disorder.

The use of an automatic remote weight management system to track treatment response, identified drugs supply shortage and its consequences: A pilot study.

Semaglutide and nonarteritic anterior ischaemic optic neuropathy.

Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data.

The GLP-1 agonist semaglutide ameliorates cognitive regression in P301S tauopathy mice model via autophagy/ACE2/SIRT1/FOXO1-Mediated Microglia Polarization.

Sleeve Gastrectomy Versus Semaglutide for Weight Loss in a Severely Obese Minority Cohort: A Propensity-Matched Study.

Changes in food preferences after oral semaglutide administration in Japanese patients with type 2 diabetes: KAMOGAWA-DM cohort.

Longitudinal Analysis of Obesity Drug Use and Public Awareness.